myelosuppressionn.
/ˌmʌɪələ(ʊ)səˈprɛʃn/, U.S. /ˈˌmaɪəloʊsəˈprɛʃ(ə)n/ Medicine.
Inhibition of the normal activity of the bone marrow (reduced haematopoiesis), usually as a result of cytotoxic chemotherapy or radiotherapy.
ΚΠ
1967 Ann. Internal Med. 67 1236/1 Bacterial endotoxin has been used to estimate the granulocyte reserves of patients receiving chemotherapeutic agents known to cause myelosuppression.
1975 Proc. National Acad. Sci. U.S.A. 72 3683/1 Regimens have been hampered by the occasional development of serious toxicities, such as neurologic sequelae, renal failure, and myelosuppression.
1987 M. J. Neal Med. Pharmacol. at Glance xxxiii. 73/2 It causes more myelosuppression than vincristine but is less neurotoxic.
2002 Cancer 94 1457 The most prominent Grade 3 and 4 toxicities were reversible myelosuppression and fatigue.
This is a new entry (OED Third Edition, June 2003; most recently modified version published online March 2022).
<
n.1967